Author

T. Yoshida

Observed name: Tatsuya Yoshida

Institution: National Cancer Center Hospital

Observed institution: National Cancer Center Hospital

OpenAlex ID: A5011152862

MA13.03 Integrated Efficacy and Safety of Brigatinib Following Alectinib Treatment in the ALTA-2 and J-ALTA Studies

2022 · S.-H.I. Ou, M. Nishio, et al. · Journal of Thoracic Oncology · 3

The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2 -mutant NSCLC: a bench-to-bedside review

2026 · John V. Heymach, Sanjay Popat, et al. · Expert Review of Anticancer Therapy · 2

1009P Integrated biomarker analysis of brigatinib efficacy in anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) refractory to alectinib

2022 · S-H.I. Ou, M. Nishio, et al. · Annals of Oncology

Works count: 3

Citation count: 5

H-index: 2

I10-index: